you are here: HomeNewsBusiness

COVID-19 Vaccine | Cadila Health says it is ‘on track’ for May submission of vaccine to DCGI

Cadila will file for emergency use authorisation after it has submitted its vaccine to the Drugs Controller General of India

May 14, 2021 / 01:02 PM IST
The country’s massive vaccination drive kicked off sluggishly in January when cases were low and exports of vaccines were high, with 64 million doses going overseas. But as infections started to rise in March and April, India's exports drastically slowed down so doses went to its own population, reaching daily record highs. So far, around 10 percent of India’s population have received one shot while just under 2.5 percent have got both. (Image: AP)

The country’s massive vaccination drive kicked off sluggishly in January when cases were low and exports of vaccines were high, with 64 million doses going overseas. But as infections started to rise in March and April, India's exports drastically slowed down so doses went to its own population, reaching daily record highs. So far, around 10 percent of India’s population have received one shot while just under 2.5 percent have got both. (Image: AP)

Cadila Health on May 14 said it is “on track” for a May-end submission of its COVID-19 vaccine to the Indian drug regulator, CNBC-TV18 reported.

As per the report, Cadila will file for an emergency use authorisation (EUA) after it has submitted its vaccine to the Drugs Controller General of India (DCGI) and is aiming to supply 5 crore doses of its candidate to India by year-end.

Follow our LIVE Updates on the coronavirus pandemic here

This is in line with the Centre’s announcement of making available more than two billion doses of COVID-19 vaccines in India, between August and December 2021.

This was stated by Niti Aayog member Dr VK Paul, who further said that the bulk of these doses – 750 million (75 crore) doses would comprise of Covishield, which is being produced by Pune-based Serum Institute of India (SII); while another 550 million (55 crore) doses of Covaxin, made by Hyderabad's Bharat Biotech, would also be available.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Below is a breakdown of the expected pipeline:
Vaccine Production/Availability (August-December 2021)India Manufacturer
Covishield75 croreSerum Institute of India
Covaxin55 croreBharat Biotech
Bio E sub vaccine30 croreBiological E
Zydus Cadila DNA vaccine5 croreZydus Cadila
Novavax vaccine20 croreSerum Institute of India
BB Nasal vaccine10 crore--
Genova mRNA vaccine6 crore--
Sputnik vaccine15.6 croreDr Reddy’s Laboratory
TOTAL216 crore
Source: PIB/Twitter
Follow our full COVID-19 coverage here
Moneycontrol News
first published: May 14, 2021 01:02 pm

stay updated

Get Daily News on your Browser
Sections